» Articles » PMID: 17059994

Oxidative Stress is Progressively Enhanced with Advancing Stages of CKD

Overview
Journal Am J Kidney Dis
Specialty Nephrology
Date 2006 Oct 25
PMID 17059994
Citations 181
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Oxidative stress appears to have a central role in the pathophysiological process of uremia and its complications, including cardiovascular disease. However, there is little evidence to suggest how early oxidative stress starts developing during the progression of chronic kidney disease (CKD). The aim of this study is to assess oxidative stress activity in a cross-sectional study of patients with CKD stages 1 to 4.

Methods: Eighty-seven steady patients (47 men, 40 women) with a median age of 62 years (range, 28 to 84 years) and mean estimated glomerular filtration rate (eGFR) of 57 mL/min (0.95 mL/s) were studied. Levels of plasma 8-isoprostanes (8-epiPGF2a) and serum total antioxidant status (TAS) were used as markers of oxidative stress. 8-epiPGF2a levels were determined by using an enzyme-linked immunosorbent assay method, whereas a chromatometric method was used to determine TAS.

Results: Plasma 8-epiPGF2a levels increased significantly as CKD stages advanced (P < 0.001). There was a highly significant inverse correlation between 8-epiPGF2a level and GFR (P < 0.01). Serum TAS levels also increased in a similar fashion (P < 0.009) and showed a significant inverse correlation with GFR (P < 0.01). 8-epiPGF2a and TAS levels showed a positive correlation (P < 0.05). Multiple regression analysis showed that the most significant predictor variable for 8-epiPGF2a level was eGFR, whereas the association between eGFR and TAS was affected strongly by confounding variables, mainly uric acid level.

Conclusion: Oxidative stress appears to increase as CKD progresses and correlates significantly with level of renal function. Increased TAS seems to be dependent on several confounding variables, including increased uric acid levels, and therefore does not seem to be a reliable method for assessing the antioxidant capacity of patients with CKD. These results suggest that larger studies using the correct markers to assess the timing and complex interplay of oxidative stress and other risk factors during the progression of CKD should be carried out.

Citing Articles

Advances in kidney disease: pathogenesis and therapeutic targets.

Boima V, Agyekum A, Ganatra K, Agyekum F, Kwakyi E, Inusah J Front Med (Lausanne). 2025; 12:1526090.

PMID: 40027896 PMC: 11868101. DOI: 10.3389/fmed.2025.1526090.


Relationship between renal oxidative stress levels and disease severity in patients with chronic kidney disease assessed by [Cu-64]ATSM PET/MRI.

Huang Y, Nishikawa Y, Mori T, Nogami M, Makino A, Kiyono Y Sci Rep. 2025; 15(1):7227.

PMID: 40021767 PMC: 11871321. DOI: 10.1038/s41598-024-85027-2.


Unraveling Ferroptosis: A New Frontier in Combating Renal Fibrosis and CKD Progression.

Jin R, Dai Y, Wang Z, Hu Q, Zhang C, Gao H Biology (Basel). 2025; 14(1).

PMID: 39857243 PMC: 11763183. DOI: 10.3390/biology14010012.


Association of composite dietary antioxidant index with mortality risk among adults with chronic kidney disease in NHANES.

Sun J, Yang H, Sun A, Guan H, Xie W, Han L Sci Rep. 2025; 15(1):2578.

PMID: 39833486 PMC: 11747494. DOI: 10.1038/s41598-025-87230-1.


Therapeutic Potential of Oligo-Fucoidan in Mitigating Peritoneal Dialysis-Associated Fibrosis.

Chen Y, Wu M, Huang N, Wu M, Hsu Y, Liao C Mar Drugs. 2024; 22(12).

PMID: 39728104 PMC: 11678284. DOI: 10.3390/md22120529.